NRD
MCRB icon

Nebula Research & Development’s Seres Therapeutics MCRB Stock Holding History

Nebula Research & Development’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-595
Closed -$67.4K – 406
2023
Q1 		$67.4K Buy
+595
New +$64.4K 0.12% 216

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Nebula Research & Development's MCRB Position: Q2 2023 in Review

Nebula Research & Development sold out of Seres Therapeutics (MCRB) in Q2 2023, closing a stake of 595 shares — an estimated $67.4K sold.

Nebula Research & Development first reported a position in MCRB in Q1 2023 and held it in 1 quarter. The position peaked at $67.4K in Q1 2023. 137 funds tracked by Wall St. Rank hold MCRB as of Q2 2023.

  • Nebula Research & Development reported no remaining Seres Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Nebula Research & Development sold 595 Seres Therapeutics shares in Q2 2023, an estimated $67.4K.
  • Nebula Research & Development first reported a position in Seres Therapeutics in Q1 2023 and held it in 1 quarter.
  • Nebula Research & Development's Seres Therapeutics position peaked at $67.4K in Q1 2023.
  • 137 funds tracked by Wall St. Rank held Seres Therapeutics as of Q2 2023.

Based on Nebula Research & Development's 13F filing for Q2 2023, filed 14 Aug 2023.